Matches in SemOpenAlex for { <https://semopenalex.org/work/W9985844> ?p ?o ?g. }
- W9985844 endingPage "183" @default.
- W9985844 startingPage "175" @default.
- W9985844 abstract "Medical management of pancreatic neuroendocrine tumors has recently been improved by new molecules of which the mTOR inhibitor everolimus. If digestive neuroendocrine tumors are rare, the incidence is in constant increase and the prevalence in digestive cancers put them right behind colorectal cancers. Everolimus has demonstrated efficacy in unresectable and progressive pancreatic neuroendocrine tumors, by doubling the median progression free survival (11 versus 4.6 months), with a median time of exposure to everolimus of nine months. Everolimus is generally maintained until progression or intolerance and some patients are treated during several years. Potential metabolic disorders induced by everolimus (dyslipidemia, hyperglycemia) in patients with life expectancy of several years, justify monitoring of these parameters and accurate treatment management algorithm. These will avoid worsening patient's prognostic, but also prematurely discontinue potentially effective treatment or contraindicate other therapeutic weapons, in a pathology in which there are multiple therapeutic options in metastatic phase. We propose a standard practice in terms of initial assessment, monitoring, care threshold, and therapeutic objectives to manage metabolic disorders, fitted to our patients with advanced pancreatic neuroendocrine tumors." @default.
- W9985844 created "2016-06-24" @default.
- W9985844 creator A5000284560 @default.
- W9985844 creator A5003323204 @default.
- W9985844 creator A5008482986 @default.
- W9985844 creator A5009182471 @default.
- W9985844 creator A5049515095 @default.
- W9985844 creator A5050532099 @default.
- W9985844 creator A5052299853 @default.
- W9985844 creator A5082610705 @default.
- W9985844 creator A5090375155 @default.
- W9985844 date "2014-02-01" @default.
- W9985844 modified "2023-09-25" @default.
- W9985844 title "Prise en charge des troubles métaboliques observés avec évérolimus chez les patients atteints de tumeurs neuroendocrines bien différenciées non résécables : propositions d’experts" @default.
- W9985844 cites W1560980352 @default.
- W9985844 cites W1783019770 @default.
- W9985844 cites W1968626722 @default.
- W9985844 cites W1996797901 @default.
- W9985844 cites W2018066433 @default.
- W9985844 cites W2022757173 @default.
- W9985844 cites W2025721435 @default.
- W9985844 cites W2043180355 @default.
- W9985844 cites W2045375909 @default.
- W9985844 cites W2071359087 @default.
- W9985844 cites W2078768940 @default.
- W9985844 cites W2079241416 @default.
- W9985844 cites W2083378657 @default.
- W9985844 cites W2085845513 @default.
- W9985844 cites W2093751336 @default.
- W9985844 cites W2107561358 @default.
- W9985844 cites W2115686439 @default.
- W9985844 cites W2118677643 @default.
- W9985844 cites W2118776368 @default.
- W9985844 cites W2124571011 @default.
- W9985844 cites W2126945216 @default.
- W9985844 cites W2127063807 @default.
- W9985844 cites W2128059625 @default.
- W9985844 cites W2128267006 @default.
- W9985844 cites W2136829490 @default.
- W9985844 cites W2148933046 @default.
- W9985844 cites W2149214723 @default.
- W9985844 cites W2155018172 @default.
- W9985844 cites W2158474413 @default.
- W9985844 cites W2171760625 @default.
- W9985844 cites W2172193326 @default.
- W9985844 cites W2198678228 @default.
- W9985844 cites W2339290868 @default.
- W9985844 cites W4244516790 @default.
- W9985844 doi "https://doi.org/10.1684/bdc.2014.1887" @default.
- W9985844 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24557872" @default.
- W9985844 hasPublicationYear "2014" @default.
- W9985844 type Work @default.
- W9985844 sameAs 9985844 @default.
- W9985844 citedByCount "8" @default.
- W9985844 countsByYear W99858442013 @default.
- W9985844 countsByYear W99858442015 @default.
- W9985844 countsByYear W99858442016 @default.
- W9985844 countsByYear W99858442018 @default.
- W9985844 countsByYear W99858442022 @default.
- W9985844 crossrefType "journal-article" @default.
- W9985844 hasAuthorship W9985844A5000284560 @default.
- W9985844 hasAuthorship W9985844A5003323204 @default.
- W9985844 hasAuthorship W9985844A5008482986 @default.
- W9985844 hasAuthorship W9985844A5009182471 @default.
- W9985844 hasAuthorship W9985844A5049515095 @default.
- W9985844 hasAuthorship W9985844A5050532099 @default.
- W9985844 hasAuthorship W9985844A5052299853 @default.
- W9985844 hasAuthorship W9985844A5082610705 @default.
- W9985844 hasAuthorship W9985844A5090375155 @default.
- W9985844 hasConcept C120665830 @default.
- W9985844 hasConcept C121332964 @default.
- W9985844 hasConcept C126322002 @default.
- W9985844 hasConcept C143998085 @default.
- W9985844 hasConcept C2779066768 @default.
- W9985844 hasConcept C2779699572 @default.
- W9985844 hasConcept C29456083 @default.
- W9985844 hasConcept C61511704 @default.
- W9985844 hasConcept C71924100 @default.
- W9985844 hasConceptScore W9985844C120665830 @default.
- W9985844 hasConceptScore W9985844C121332964 @default.
- W9985844 hasConceptScore W9985844C126322002 @default.
- W9985844 hasConceptScore W9985844C143998085 @default.
- W9985844 hasConceptScore W9985844C2779066768 @default.
- W9985844 hasConceptScore W9985844C2779699572 @default.
- W9985844 hasConceptScore W9985844C29456083 @default.
- W9985844 hasConceptScore W9985844C61511704 @default.
- W9985844 hasConceptScore W9985844C71924100 @default.
- W9985844 hasIssue "2" @default.
- W9985844 hasLocation W99858441 @default.
- W9985844 hasLocation W99858442 @default.
- W9985844 hasOpenAccess W9985844 @default.
- W9985844 hasPrimaryLocation W99858441 @default.
- W9985844 hasRelatedWork W1912172143 @default.
- W9985844 hasRelatedWork W1998085187 @default.
- W9985844 hasRelatedWork W2043171019 @default.
- W9985844 hasRelatedWork W2058233712 @default.
- W9985844 hasRelatedWork W2284646457 @default.
- W9985844 hasRelatedWork W2719368655 @default.